Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
Twenty-six previously treated patients with refractory small cell lung cancer (SCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. Twenty-five patients had prior exposure to cisplatin plus etoposide, and 14 of the 26 patients (54%) had prior therapy with CAV (cyclophosphamide, doxorubicin, and vincristine). Nonhematologic toxicity was mild; the dose-limiting toxicity was granulocytopenia. One complete response and five partial responses were seen (duration, 6 to 20 weeks), for an overall response rate of 23%. We conclude that daily oral etoposide is a well-tolerated and easily administered drug in refractory SCLC and has definite therapeutic activity.
Einhorn
L H
LH
Hoosier Oncology Group, Walther Cancer Institute, Indianapolis, IN 46208.
Pennington
K
K
McClean
J
J
D000284:Administration, Oral; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012074:Remission Induction; D015996:Survival Rate
D005047:Etoposide